Positron emission tomography/computed tomography and endobronchial ultrasound-guided transbronchial needle aspiration to evaluate the status of N2 in preoperative non-small cell lung cancer: a diagnostic test

Background As a minimally invasive method, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was more accurate than non-invasive methods such as positron emission tomography (PET) and computed tomography (CT) to evaluate the lymph nodes in preoperative non-small cell lung cancer (NSCLC). PET/CT has more anatomical advantages than PET scanning and is more accurate in lung cancer staging. However, no relevant studies have comparatively evaluated PET/CT and EBUS-TBNA for NSCLC patients. Methods A total of 112 patients were included in this retrospective analysis. The golden diagnosis of N2 status was postoperative pathological results. In EBUS-TBNA puncture specimens, if clear malignant tumor cells could be seen, the results were taken as positive. In PET/CT image analysis, the CT values, short diameter, and maximum standardized uptake value (SUVmax) of each lymph node were recorded to evaluate N2 status. The results of PET/CT and EBUS-TBNA were compared with the final pathological results, and respective sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. - Then, the patients were divided into adenocarcinoma group and squamous cell carcinoma group -and the results were calculated and compared with the above method. Results The results showed that EBUS-TBNA had a higher diagnostic value for mediastinal lymph nodes than PET/CT, and the difference was statistically significant (P<0.001). In NSCLC patients, the results showed that the sensitivity (P=0.013), specificity (P<0.001), PPV (P<0.001), NPV (P<0.001), and accuracy (P<0.001) of EBUS-TBNA were higher than that of PET/CT (AUC =0.954 and 0.636, respectively). In adenocarcinoma cases, specificity (P<0.001), PPV (P<0.001), NPV (P<0.001), and accuracy (P<0.001) of EBUS-TBNA were higher than that of PET/CT (AUC =0.957 and 0.596, respectively).In cases with squamous cell carcinoma, specificity (P=0.003), PPV (P<0.001), and accuracy (P<0.001) of EBUS-TBNA were higher than PET/CT (AUC =0.952 and 0.657, respectively). Conclusions For preoperative diagnosis of mediastinal lymph node metastases in NSCLC, EBUS-TBNA is more accurate than PET/CT. For those patients with suspected mediastinal lymph node metastasis, EBUS-TBNA should be preferred method to evaluate the status of mediastinal lymph nodes.

[1]  G. Watte,et al.  MRI-based differentiation between lymphoma and sarcoidosis in mediastinal lymph nodes , 2021, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[2]  P. V. Van Schil,et al.  Evaluation of mediastinoscopy in mediastinal lymph node staging for non-small-cell lung cancer. , 2020, Interactive cardiovascular and thoracic surgery.

[3]  S. Motoyama,et al.  Approaches to resection of recurrent solitary mediastinal lymph nodes after esophagectomy , 2020, Esophagus.

[4]  J. Cho,et al.  Preoperative Risk Factors for Pathologic N2 Metastasis in Positron Emission Tomography-Computed Tomography–Diagnosed N0–1 Non-Small Cell Lung Cancer , 2019, The Korean journal of thoracic and cardiovascular surgery.

[5]  Daniel P Steinfort,et al.  Preoperative Staging by EBUS in cN0/N1 Lung Cancer , 2019, Journal of bronchology & interventional pulmonology.

[6]  Qinghua Zhou,et al.  Lung Adenocarcinoma has a Higher Risk of Lymph Node Metastasis than Squamous Cell Carcinoma: A Propensity Score-Matched Analysis , 2018, World Journal of Surgery.

[7]  F. Petrella,et al.  Endobronchial Ultrasound Transbronchial Needle Aspiration in Thoracic Diseases: Much More than Mediastinal Staging , 2018, Canadian respiratory journal.

[8]  Kenji Suzuki,et al.  Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer , 2017, Japanese journal of clinical oncology.

[9]  Yi-Song Wang,et al.  Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations , 2017, Scientific Reports.

[10]  M. Infante,et al.  Ideal conditions to perform EBUS-TBNA. , 2017, Journal of thoracic disease.

[11]  Jérémie F. Cohen,et al.  Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis. , 2016, The Lancet. Respiratory medicine.

[12]  Yiming Ni,et al.  Distribution and prognosis of mediastinal lymph node metastases of nonsmall cell lung cancer. , 2016, Journal of cancer research and therapeutics.

[13]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[14]  N. Slavova-Azmanova,et al.  Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: a pragmatic pre-post study , 2016, BMC Cancer.

[15]  X. Cui,et al.  Ultrasound techniques in the evaluation of the mediastinum, part 2: mediastinal lymph node anatomy and diagnostic reach of ultrasound techniques, clinical work up of neoplastic and inflammatory mediastinal lymphadenopathy using ultrasound techniques and how to learn mediastinal endosonography. , 2015, Journal of thoracic disease.

[16]  X. Cui,et al.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques. , 2015, Journal of thoracic disease.

[17]  C. Dooms,et al.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  Jai-Hyuen Lee,et al.  Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma. , 2012, Nuclear medicine and biology.

[19]  Jianxing He,et al.  [Value of endobronchial ultrasound-transbronchial needle aspiration biopsy for diagnosis of PET-CT positive mediastinal lymph nodes]. , 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[20]  Moon Soo Kim,et al.  Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. , 2009, Chest.

[21]  D. Wood,et al.  Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  F. Herth,et al.  Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. , 2008, Chest.

[23]  A. Demir,et al.  Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer. , 2008, European Journal of Cardio-Thoracic Surgery.

[24]  L. Quint Staging non-small cell lung cancer* , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[25]  Michael K Gould,et al.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[26]  Takehiko Fujisawa,et al.  Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. , 2006, Chest.

[27]  L. Molins,et al.  The Yield of Mediastinoscopy with Respect to Lymph Node Size, Cell Type, and the Location of the Primary Tumor , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.